Intra-Anally Administered Artesunate in Patients With High-Grade Anal Intraepithelial Neoplasia (AIN 2/3)
This open label study investigates a novel non-surgical approach to the treatment of HPV-associated anal intraepithelial neoplasia, using Artesunate suppositories.
HPV-Related Anal Intraepithelial Neoplasia|AIN2/3|Artesunate|Alternative Treatment|Anal Dysplasia|Precancerous Conditions|Human Papilloma Virus
DRUG: Artesunate Suppositories
Incidence of treatment-emergent adverse events (Safety and tolerability) of Artesunate suppositories for the treatment of anal intraepithelial neoplasia (AIN2/3), Number of patients with serious adverse events or dose limiting toxicities related to the study medication, according to CTCAE4.0, 6 weeks from the date of the first dosing
Number of patients with histologic regression of anal intraepithelial neoplasia (AIN2/3) to AIN1 or less, Number of patients with no AIN2/3 as assessed by high resolution anoscopy and biopsy, 16 weeks|Number of patients with histologic regression of anal intraepithelial neoplasia (AIN2/3) to AIN1 or less, Number of patients with no AIN2/3 as assessed by high resolution anoscopy and biopsy, 28 weeks|Number of patients with viral clearance of human papillomavirus (HPV) virus measured by HPV genotyping, Number of patients with HPV genotypes present at study entry which become undetectable during the study window, 40 weeks
Patients diagnosed with AIN 2/3 will be enrolled sequentially in treatment cohorts receiving different doses of Artesunate suppositories administered trans-anally. Doses of escalation will be 200 mg, 400 mg, and 600 mg. Treatment cohorts will consist of 2 or 3 cycles at each dose level. Suppositories will be administered daily for 5 days. Five days constitutes 1 cycle. Up to 3 cycles will be administered at Weeks 0, 2, and 4.